These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
139 related articles for article (PubMed ID: 10394006)
1. Minimum inhibitory and minimal lethal concentration against Chlamydia trachomatis dependent on the time of addition and the duration of the presence of antibiotics. Notomi T; Ikeda Y; Nagayama A Chemotherapy; 1999; 45(4):242-8. PubMed ID: 10394006 [TBL] [Abstract][Full Text] [Related]
2. In vitro evaluation of activities of azithromycin, clarithromycin and sparfloxacin against Chlamydia trachomatis. Lefèvre JC; Escaffre MC; Courdil M; Lareng MB Pathol Biol (Paris); 1993 Apr; 41(4):313-5. PubMed ID: 8233628 [TBL] [Abstract][Full Text] [Related]
3. Association of the in vitro susceptibility of clinical isolates of chlamydia trachomatis with serovar and duration of antibiotic exposure. Zheng H; Xue Y; Bai S; Qin X; Lu P; Yang B Sex Transm Dis; 2015 Mar; 42(3):115-9. PubMed ID: 25668641 [TBL] [Abstract][Full Text] [Related]
4. In vitro susceptibility of recent clinical isolates of Chlamydia trachomatis to macrolides and tetracyclines. Samra Z; Rosenberg S; Soffer Y; Dan M Diagn Microbiol Infect Dis; 2001 Mar; 39(3):177-9. PubMed ID: 11337185 [TBL] [Abstract][Full Text] [Related]
5. Chlamydia trachomatis: in vitro susceptibility of genital and ocular isolates to some quinolones, amoxicillin and azithromycin. Børsum T; Dannevig L; Størvold G; Melby K Chemotherapy; 1990; 36(6):407-15. PubMed ID: 1963393 [TBL] [Abstract][Full Text] [Related]
6. [Comparative study of minimal inhibiting concentrations of doxycycline, ofloxacin and erythromycin against 18 recent isolates from Chlamydia trachomatis (1994-1995)]. Bianchi A; Legouge R; Lefevre JC; Askienazy-Elbhar M; Joly-Guillou ML; Pavis A; Sednaoui P Pathol Biol (Paris); 1996 May; 44(5):347-50. PubMed ID: 8758473 [TBL] [Abstract][Full Text] [Related]
7. Chlamydia trachomatis antimicrobial susceptibility in colorectal and endocervical cells. Foschi C; Salvo M; Cevenini R; Marangoni A J Antimicrob Chemother; 2018 Feb; 73(2):409-413. PubMed ID: 29077843 [TBL] [Abstract][Full Text] [Related]
8. High treatment failure rate is better explained by resistance gene detection than by minimum inhibitory concentration in patients with urogenital Chlamydia trachomatis infection. Shao L; You C; Cao J; Jiang Y; Liu Y; Liu Q Int J Infect Dis; 2020 Jul; 96():121-127. PubMed ID: 32173573 [TBL] [Abstract][Full Text] [Related]
9. Phenotypic antimicrobial susceptibility testing of Chlamydia trachomatis isolates from patients with persistent or successfully treated infections. Pitt R; Alexander S; Ison C; Horner P; Hathorn E; Goold P; Woodford N; Cole MJ J Antimicrob Chemother; 2018 Mar; 73(3):680-686. PubMed ID: 29207004 [TBL] [Abstract][Full Text] [Related]
10. In vitro susceptibility of Mycoplasma hominis clinical isolates to tetracyclines, quinolones and macrolides. Samra Z; Rosenberg S; Soffer Y Diagn Microbiol Infect Dis; 2002 Dec; 44(4):359-61. PubMed ID: 12543541 [TBL] [Abstract][Full Text] [Related]
11. In vitro activity of fluoroquinolones, azithromycin and doxycycline against chlamydia trachomatis cultured from men with chronic lower urinary tract symptoms. Smelov V; Perekalina T; Gorelov A; Smelova N; Artemenko N; Norman L Eur Urol; 2004 Nov; 46(5):647-50. PubMed ID: 15474277 [TBL] [Abstract][Full Text] [Related]
12. In vitro activity of CEM-101, a new fluoroketolide antibiotic, against Chlamydia trachomatis and Chlamydia (Chlamydophila) pneumoniae. Roblin PM; Kohlhoff SA; Parker C; Hammerschlag MR Antimicrob Agents Chemother; 2010 Mar; 54(3):1358-9. PubMed ID: 20038627 [TBL] [Abstract][Full Text] [Related]
13. In vitro activity of azithromycin (CP-62,993) against Chlamydia trachomatis and Chlamydia pneumoniae. Agacfidan A; Moncada J; Schachter J Antimicrob Agents Chemother; 1993 Sep; 37(9):1746-8. PubMed ID: 8239579 [TBL] [Abstract][Full Text] [Related]
14. In vitro activities of azithromycin, clarithromycin, L-ofloxacin, and other antibiotics against Chlamydia pneumoniae. Hammerschlag MR; Qumei KK; Roblin PM Antimicrob Agents Chemother; 1992 Jul; 36(7):1573-4. PubMed ID: 1324650 [TBL] [Abstract][Full Text] [Related]
15. In vitro susceptibility of Chlamydia pecorum to macrolides, tetracyclines, quinolones and beta-lactam. Pudjiatmoko ; Fukushi H; Ochiai Y; Yamaguchi T; Hirai K Microbiol Immunol; 1998; 42(1):61-3. PubMed ID: 9525782 [TBL] [Abstract][Full Text] [Related]
16. In vitro activity of Brucella melitensis isolates to various antimicrobials in Turkey. Denk A; Demirdag K; Kalkan A; Ozden M; Cetinkaya B; Kilic SS Infect Dis (Lond); 2015 Jun; 47(6):364-9. PubMed ID: 25712728 [TBL] [Abstract][Full Text] [Related]
17. [Bacteriostatic and bactericidal activities of cyclines, macrolides and fluoroquinolones against Chlamydia trachomatis]. Dailloux M; Villemain P Pathol Biol (Paris); 1992 May; 40(5):455-60. PubMed ID: 1495827 [TBL] [Abstract][Full Text] [Related]
19. In vitro activities of several antimicrobial agents against recently isolated and genotyped Chlamydia trachomatis urogenital serovars D through K. Donati M; Di Francesco A; D'Antuono A; Delucca F; Shurdhi A; Moroni A; Baldelli R; Cevenini R Antimicrob Agents Chemother; 2010 Dec; 54(12):5379-80. PubMed ID: 20855744 [TBL] [Abstract][Full Text] [Related]
20. Prediction of efficacy of antimicrobial agents in treatment of infections due to Chlamydia trachomatis. Bowie WR; Lee CK; Alexander ER J Infect Dis; 1978 Nov; 138(5):655-9. PubMed ID: 712119 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]